Journal Article

Potentiation of tumor formation by topical administration of 15-deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> in a model of skin carcinogenesis

Olga Millán, Daniel Rico, Héctor Peinado, Natasha Zarich, Konstantinos Stamatakis, Dolores Pérez-Sala, José M. Rojas, Amparo Cano and Lisardo Boscá

in Carcinogenesis

Volume 27, issue 2, pages 328-336
Published in print February 2006 | ISSN: 0143-3334
Published online August 2005 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgi213
Potentiation of tumor formation by topical administration of 15-deoxy-Δ12,14-prostaglandin J2 in a model of skin carcinogenesis

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

The effect of prostaglandins on the development of papillomas has been investigated in mice receiving prostaglandins E2 (PGE2) or the cyclopentenone 15-deoxy-Δ12,14-PGJ2 (15dPGJ2) topically, using the 7,12-dimethylbenz[a]anthracene (DMBA)-induced tetradecanoylphorbol acetate (TPA)-promoted model of skin carcinogenesis. The presence of 15dPGJ2 during DMBA and TPA treatment inhibited apoptosis and increased the rate, number, size and vascularization of the papillomas, some of them progressing into carcinomas. Moreover, skin sections from mice treated for one week with DMBA and 15dPGJ2 showed a much reduced rate of apoptotic cells, and an enhanced expression of vascular epithelial growth factor when compared with animals receiving DMBA, with or without PGE2. The analysis of molecular events in the MCA3D keratinocyte cell line showed that 15dPGJ2 activated Ras and improved cell viability by inhibiting DMBA-dependent apoptosis. In addition to this, cell adhesion was impaired in MCA3D keratinocytes co-treated with 15dPGJ2 and DMBA, at the same time when the expression of cyclooxygenase-2 (COX-2) was observed under these conditions. These effects mediated by 15dPGJ2 might contribute to understand the role of COX-2 metabolites in carcinogenesis, leading to an increase of cell viability after mutagenic injury and therefore in the progression of tumors.

Keywords: COX-2, cyclooxygenase-2; CyPG, cyclopentenone PG; 15dPGJ2, 15-deoxy-Δ12,14-PGJ2; DMBA, 7,12-dimethylbenz[a]anthracene; MMP9, matrix metalloproteinase-9; PG, prostaglandins; PGE2/PGJ2, prostaglandin E2/J2; TPA, tetradecanoylphorbol acetate; VEGF, vascular epithelial growth factor

Journal Article.  5939 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.